Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables - Other (2018 - 2020)

Historic Receivables - Other for Revolution Medicines (RVMD) over the last 3 years, with Q4 2020 value amounting to $6.4 million.

  • Revolution Medicines' Receivables - Other fell 2682.84% to $6.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $6.4 million, marking a year-over-year decrease of 2682.84%. This contributed to the annual value of $6.4 million for FY2020, which is 2682.84% down from last year.
  • According to the latest figures from Q4 2020, Revolution Medicines' Receivables - Other is $6.4 million, which was down 2682.84% from $9.3 million recorded in Q3 2020.
  • In the past 5 years, Revolution Medicines' Receivables - Other ranged from a high of $9.3 million in Q3 2020 and a low of $6.4 million during Q4 2020
  • In the last 3 years, Revolution Medicines' Receivables - Other had a median value of $7.9 million in 2020 and averaged $7.9 million.
  • Per our database at Business Quant, Revolution Medicines' Receivables - Other skyrocketed by 1963.58% in 2019 and then tumbled by 2682.84% in 2020.
  • Over the past 3 years, Revolution Medicines' Receivables - Other (Quarter) stood at $7.3 million in 2018, then rose by 19.64% to $8.7 million in 2019, then fell by 26.83% to $6.4 million in 2020.
  • Its Receivables - Other stands at $6.4 million for Q4 2020, versus $9.3 million for Q3 2020 and $7.3 million for Q2 2020.